What You Should Know:
– BioPhy, an AI drug development company, and Every Cure, a non-profit dedicated to unlocking the potential of existing drugs for new uses, today announced a strategic partnership to revolutionize drug repurposing through artificial intelligence (AI).
– The partnership follows Every Cure’s recent funding from the Advanced Research Projects Agency for Health (ARPA-H). A successful pilot using AI led to the identification of potential treatments for diseases like sickle cell disease, ALS, and autism spectrum disorder.
Unlocking Hidden Cures on the Pharmacy Shelf
Every Cure aims to identify new uses for existing medications, potentially saving patients from suffering while effective treatments remain undiscovered. This partnership will leverage BioPhy’s BioLogicAI platform to:
- Identify Promising Drug-Disease Matches: BioLogicAI’s AI engine will help Every Cure evaluate potential repurposing opportunities with high value.
- Optimize Clinical Trials: The partnership will focus on simulating and optimizing clinical trials for these potential new uses, maximizing success rates and reducing costs.
BioLogicAI: A Powerful Tool for Drug Development
BioLogicAI is a comprehensive AI engine that offers a range of benefits for life science companies:
- Clinical Trial Endpoint Predictability: BioLogicAI predicts successful clinical trial endpoints, a critical factor in drug development.
- Informed Decision-Making: The platform provides data-driven insights for various stages of drug development, including indication selection, licensing, and asset management.
- Benchmarking Preclinical Assets: BioLogicAI compares preclinical drug candidates to existing drugs and FDA-approved medications, informing development strategies.
Enhancing Drug Repurposing with AI
This collaboration will focus on several key areas to advance drug repurposing with AI:
- Building AI Infrastructure: The partnership will establish public and private benchmark datasets and knowledge graphs, crucial for AI development.
- Data Integration: Proprietary and novel data will be incorporated into the AI platform to enhance its capabilities.
- Refining Drug-Disease Matching: Ranking algorithms for drug-disease queries will be further optimized.
- Simulated Clinical Trials: AI will be used to simulate and optimize clinical trials for potential drug repurposing candidates.
“At BioPhy, we’re committed to creating a world where pharmaceutical companies won’t be forced to waste billions of dollars as a result of failed clinical trials. Every Cure shares that mission, while also unlocking new ways FDA-approved drugs can be used to accelerate treatment to patients suffering from diseases,” said Dave Latshaw II, CEO and Co-Founder of BioPhy. “We look forward to partnering with Every Cure to uncover even more diseases that all existing drugs can treat.”
